Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Vaccine 130

Vaccine Vaccination Containment Immune Response 130

Roots Analysis

FEBRUARY 27, 2024

What are Affimers : Affimers are small proteins that target and bind molecules on cellular surfaces in a manner analogous to monoclonal antibodies. In nature, they are made by a group of bacteria known as actinomycetes. The key difference is that affimers are optimized to enhance their structural stability.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Roots Analysis

OCTOBER 16, 2023

Biopharmaceutical filtration is a critical step in the production of biopharmaceuticals, including proteins, antibodies, and vaccines. Membrane Filters: Membrane filters are typically used for sterilization and removal of smaller impurities such as bacteria and viruses. are used to remove any residual bacteria, viruses, or endotoxins.

Bacteria 40

Bacteria Production Protein Contamination 40

The Pharma Data

OCTOBER 14, 2020

VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. VBL is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies. CARB-X will provide Polyphor with initial funding of up to $2.62

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98